GBA's "2021 Stock Phantasma"

Guest Analyst! If you spend any amount of time on YouTube looking at companies you will spot all kind of self proclaimed stock experts! First you take a silly picture of yourself gaping at a rising chart and then you just basically read the press releases and say I'm an analyst. It's super annoying and the one's that think they are chartests are the absolute worst. But I found this guy I like because he does a good job of presenting both sides of the argument and has a nifty little hand writing marker trick that keeps your attention....

India is the big deal here... and the stk is SKILLZ.>
 
Why we don't invest live in the street. What incredible pressure! > This kid where is he now. ? I want to do a NETFLIX documentary on this guy--- this poor guy! The pressure... all star game everyone watching it's just like Elite Trader but bigger! and ... oh... man...

 
Now a million dollars gets in your head-- I know! I've been struggling to get my account to that level and then the market always crashes. It's impossible!!!

What about a super big ass TV? And what about a very cool girl...
 
came within a whisker of buying this cheap the other day.

I have it always on my list for sell offs... But I missed it,>

Floor & Decor price target raised to $118 from $111 at Jefferies 08:26 FND Jefferies analyst Jonathan Matuszewski raised the firm's price target on Floor & Decor to $118 from $111 and keeps a Buy rating on the shares, noting that quarterly search interest for "flooring installation" hit an all-time high in Q1 and adding that the Q2 set up "looks good too" as search trends indicate that the pipeline for near-term flooring installs appears favorable. He has raised his first half estimates for Floor & Decor above consensus citing his analysis of web traffic, consumer search insights, and store calls, Matuszewski tells investors.
 
This has been on a tear since we gave out a massive buy signal at $48 in the last thread!

Silicon Motion price target raised to $88 from $75 at B. Riley » 08:01 SIMO
 
Surface Oncology's immunotherapy product candidates show promising data in tumor activity
Apr. 09, 2021 8:28 AM ETSurface Oncology, Inc. (SURF)
  • Surface Oncology(NASDAQ:SURF)will present preclinical findings supporting its lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39) at theAmerican Association for Cancer Research (AACR) 2021 Annual Meeting.
  • Presentation summaries are as follows:
  • SRF617 is a potent inhibitor of CD39 enzymatic activity bothin vitroandin vivo.
  • CD39 inhibition predominantly shaped the transcriptional landscape of myeloid cells and dendritic cells, and generally induced proinflammatory conditions ad thereby support future clinical studies of SRF617 for treating patients with cancer.
  • IL-27 signaling suppresses natural killer (NK) cells within the tumor microenvironment, promoting hepatocellular carcinoma (HCC) developmentin vivo.
  • Inhibiting IL-27 signaling leads to tumor growth inhibition and suppressed HCC development in a non-alcoholic steatohepatitis-driven HCC model with concomitant enhancement of NK cell activity.
  • These findings indicate that IL-27 blockade regulates NK cell-mediated control of HCC and is a promising therapeutic target in liver cancer.
 
When my boy is done with high school, I should change my residency to Ct because I will be spending more time there than NYC-

Highest tax rates in the nation come to New York City
 
You must log in or register to reply here.
Back
Top